Anika Therapeutics Announces Date for First-Quarter Results and Conference Call.Business Editors WOBURN, Mass.--(BUSINESS WIRE)--May 10, 2001 Anika Therapeutics Inc. (Nasdaq:ANIK ANIK Canadian COMSAT ) today said it plans to issue first-quarter results before the opening of the market on May 14, 2001. The company plans to hold a conference call that same day at 10:30 a.m. Eastern Time to discuss quarterly financial results, business highlights and outlook. In addition, the company may answer one or more questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed. To listen to the conference call, dial 212/346-7480 approximately 10 minutes before the starting time and reference Anika Therapeutics. A playback of the call will be available from 12:30 p.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT Monday, May 14, through 12:30 p.m. EDT Friday, May 18. To listen to the recorded call, dial 800/633-8284, access code 18846940. About Anika Therapeutics Anika Therapeutics (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid hyaluronic acid: see mucopolysaccharide. Hyaluronic acid A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints. (HA), a naturally occurring, biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. polymer found throughout the body. In addition to ORTHOVISC(R), a treatment for osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the knee (not approved for sale in the United States), Anika markets HYVISC(R) in the United States for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica Inc. and manufactures AMVISC(R) and AMVISC(R) Plus, HA viscoelastic Adj. 1. viscoelastic - having viscous as well as elastic properties natural philosophy, physics - the science of matter and energy and their interactions; "his favorite subject was physics" products for ophthalmic surgery, for Bausch & Lomb Surgical. STAARVISC(TM)-II, an injectable ophthalmic viscoelastic, is produced for STAAR STAAR Second Time Around Aussie Rescue, Inc. (Bryan, TX) STAAR Space Technology Applications Astronomy & Rocket Research (Scottish Rocket Programme) Surgical Co. Therapies currently under development include INCERT(R), a family of potential HA products designed to prevent post-surgical adhesions. Anika is also collaborating with Orquest Inc. to manufacture OSSIGEL(R), an injectable formulation of basic fibroblast growth factor Basic fibroblast growth factor, also known as bFGF or FGF2, is a member of the fibroblast growth factor family. In normal tissue, basic fibroblast growth factor is present in basement membranes and in the subendothelial extracellular matrix of blood combined with HA designed to accelerate the healing of bone fractures, which is also under development. The statements made in this news release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve known and unknown risks, uncertainties and other factors. The words "believe," "will," "would," "expect," "anticipate," "intend," "estimate," "seek" and other expressions that are predictions of or indicate future events and trends and that do not constitute historical matters identify forward-looking statements. The company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors. There can be no assurances that: (i) additional clinical data will support the efficacy of ORTHOVISC(R), (ii) the company will undertake any clinical trials of INCERT(R), (iii) it will be able to successfully complete any clinical trials of ORTHOVISC(R) or INCERT(R), or (iv) additional clinical trials will support a PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy application and/or FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval in a timely manner or at all. Further, there can be no assurance that the company will achieve meaningful sales of STAARVISC II, or that product development efforts will be successful. Certain other factors that might cause the company's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors and Certain Factors Affecting Future Operating Results" and "Management's Discussion and Analysis Management's discussion and analysis (MD&A) A report from management to shareholders that accompanies the firm's financial statements in the annual report. It explains the period's financial results and enables management to discuss topics that may not be apparent in the financial of Financial Condition and Results of Operations" in the company's annual report on Form 10-K for the year ended Dec. 31, 2000, as well as those described in the company's news releases and other SEC filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion